ATE315405T1 - Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung - Google Patents

Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung

Info

Publication number
ATE315405T1
ATE315405T1 AT99939711T AT99939711T ATE315405T1 AT E315405 T1 ATE315405 T1 AT E315405T1 AT 99939711 T AT99939711 T AT 99939711T AT 99939711 T AT99939711 T AT 99939711T AT E315405 T1 ATE315405 T1 AT E315405T1
Authority
AT
Austria
Prior art keywords
compositions
methods
saponin adjuvants
cpg
immunostimulatory oligonucleotides
Prior art date
Application number
AT99939711T
Other languages
English (en)
Inventor
Charlotte A Kensil
Original Assignee
Antigenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigenics Inc filed Critical Antigenics Inc
Application granted granted Critical
Publication of ATE315405T1 publication Critical patent/ATE315405T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AT99939711T 1998-08-10 1999-08-06 Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung ATE315405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9591398P 1998-08-10 1998-08-10
US12860899P 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
ATE315405T1 true ATE315405T1 (de) 2006-02-15

Family

ID=26790746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99939711T ATE315405T1 (de) 1998-08-10 1999-08-06 Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung

Country Status (11)

Country Link
US (2) US7049302B1 (de)
EP (1) EP1104306B1 (de)
JP (1) JP4620251B2 (de)
AT (1) ATE315405T1 (de)
AU (1) AU773204C (de)
CA (1) CA2340174C (de)
DE (1) DE69929444T2 (de)
DK (1) DK1104306T3 (de)
ES (1) ES2257068T3 (de)
PT (1) PT1104306E (de)
WO (1) WO2000009159A1 (de)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
PT1104306E (pt) * 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7083796B2 (en) 2000-06-20 2006-08-01 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
PT1187629E (pt) * 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
NZ520976A (en) * 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
CA2397374A1 (en) * 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AR029540A1 (es) 2000-06-28 2003-07-02 Corixa Corp COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
AU2002244337B2 (en) * 2000-10-18 2005-08-11 Glaxosmithkline Biologicals S.A. Vaccines
SI2266603T1 (sl) * 2000-10-18 2012-12-31 Glaxosmithkline Biologicals S.A. Tumorska cepiva
JP2005504513A (ja) 2001-05-09 2005-02-17 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
DK2224012T3 (da) 2001-12-17 2013-05-13 Corixa Corp Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
US20060210555A1 (en) * 2001-12-21 2006-09-21 Antigenics, Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
BR0311995A (pt) * 2002-06-20 2005-04-05 Cytos Biotechnology Ag Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
JP2005532405A (ja) * 2002-07-10 2005-10-27 アクゾ・ノベル・エヌ・ベー 融合タンパク質とサポニンアジュバントとを含む免疫原性組成物
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
AU2004226605A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US7973016B2 (en) 2004-01-23 2011-07-05 Joslin Diebetes Center Methods of treating, reducing, or preventing autoimmune conditions
EP2269638A3 (de) 2004-05-28 2012-06-13 GlaxoSmithKline Biologicals S.A. Impfstoffzusammensetzungen mit Virosomen und einem Saponin-Adjuvans
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
WO2007140958A2 (en) 2006-06-02 2007-12-13 Glaxosmithkline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy
US20090142362A1 (en) * 2006-11-06 2009-06-04 Avant Immunotherapeutics, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
WO2008131074A1 (en) 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
JP5331105B2 (ja) * 2007-05-24 2013-10-30 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 凍結乾燥抗原組成物
AU2008300397A1 (en) 2007-09-17 2009-03-26 Glaxosmithkline Biologicals S.A. Improved detection of MAGE-A expression
ES2569907T3 (es) 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
AR074844A1 (es) * 2008-12-23 2011-02-16 Intervet Int Bv Composiciones farmaceuticas con saponinas
EP2202298A1 (de) 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Rekombinantes Virus der klassischen Schweinepest (KSP) mit einem modifizierten E2-Protein und Verfahren zur Erzeugung des besagten Klassiche-Schweinepest-Virus
SG174877A1 (en) 2009-03-17 2011-11-28 Mdxhealth Sa Improved detection of gene expression
RU2612521C2 (ru) 2009-07-06 2017-03-09 Онтории, Инк. Новые пролекарства нуклеиновых кислот и способы их применения
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
EP2575878B1 (de) 2010-05-28 2018-06-13 Zoetis Belgium S.A. Impstoffe mit cholesterin und cpg als einzige adjuvans-träger moleküle
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2637687B1 (de) 2010-11-08 2021-01-06 Infectious Disease Research Institute Impfstoffe mit nichtspezifischer nukleosidhydrolase und sterol-24-c-methyltransferase (smt)-polypeptiden zur behandlung und diagnose von leishmaniose
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
CN103796657B (zh) 2011-07-19 2017-07-11 波涛生命科学有限公司 合成官能化核酸的方法
PL2872485T3 (pl) 2012-07-13 2021-05-31 Wave Life Sciences Ltd. Asymetryczna grupa pomocnicza
KR102213609B1 (ko) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 키랄 제어
HUE065746T2 (hu) 2012-08-03 2024-06-28 Access To Advanced Health Inst Készítmények és eljárások aktív mycobacterium tuberculosis fertõzés kezelésére
WO2014052453A1 (en) 2012-09-25 2014-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
EP2978447B1 (de) 2013-03-28 2019-05-08 Infectious Disease Research Institute Impfstoffe mit leishmania-polypeptiden zur behandlung und diagnose von leishmaniase
UA130246C2 (uk) 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
JPWO2015108047A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
JPWO2015108048A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
SI3148579T1 (sl) 2014-05-28 2021-07-30 Agenus Inc. Proti GITR antitelesa in postopki z njihovo uporabo
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
KR20170105107A (ko) * 2015-02-26 2017-09-18 더백스 제네틱스 백신 코포레이션, 엘티디. 항원-특이적인 t-세포 반응을 도출하는 데 사용하기 위한 면역원성 단백질 및 조합 아주반트를 포함하는 백신 조성물
EA201792501A1 (ru) 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
CA2986961C (en) 2015-05-26 2023-07-25 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
CN108883173B (zh) 2015-12-02 2022-09-06 阿吉纳斯公司 抗体和其使用方法
JP2019521095A (ja) 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
EP3464360B1 (de) 2016-05-27 2025-11-12 Agenus Inc. Anti-tim-3-antikörper und verfahren zur verwendung davon
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
JP7066696B2 (ja) 2016-10-11 2022-05-13 アジェナス インコーポレイテッド 抗ｌａｇ－３抗体及びその使用方法
JP2020503883A (ja) 2017-01-13 2020-02-06 アジェナス インコーポレイテッド Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
LT3618863T (lt) 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
CN107537035A (zh) * 2017-08-30 2018-01-05 北京恩元华生物科技有限公司 复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
CA3073055A1 (en) 2017-09-04 2019-03-07 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
KR20200117981A (ko) 2017-11-03 2020-10-14 다케다 백신즈 인코포레이티드 지카 백신 및 면역원성 조성물, 그리고 이를 이용하는 방법들
MA52363A (fr) 2018-04-26 2021-03-03 Agenus Inc Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
TW202122420A (zh) 2019-08-30 2021-06-16 美商艾吉納斯公司 抗ｃｄ９６抗體及其使用方法
CN112972671B (zh) * 2019-12-13 2024-04-19 远大赛威信生命科学(南京)有限公司 药物组合物及其用途
CN113058033B (zh) * 2019-12-16 2024-07-09 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
AU2021321944A1 (en) 2020-08-07 2023-04-06 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
EP4326237A4 (de) * 2021-04-23 2025-02-26 Flow Pharma Inc. Mikrokugelformulierungen mit mehreren ungleichen peptiden und verfahren zur herstellung davon

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
JP2001505401A (ja) * 1993-09-20 2001-04-24 シー． リード，ジョン ｂｃ１−２遺伝子発現の調節
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (de) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatorische Oligonukleotide
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5968909A (en) * 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69828507T2 (de) 1997-05-20 2006-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
EP1003531B1 (de) * 1997-05-20 2007-08-22 Ottawa Health Research Institute Verfahren zur Herstellung von Nukleinsäurekonstrukten
EP1003850B1 (de) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitoren von immunstimulatorischen dna sequenz aktivität
CA2302522C (en) 1997-08-29 2010-08-17 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
AU760549B2 (en) * 1998-04-03 2003-05-15 University Of Iowa Research Foundation, The Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
JP2002514397A (ja) 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
SI1077722T1 (sl) * 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20010034330A1 (en) 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
PT1104306E (pt) * 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
AU6425999A (en) 1998-10-09 2000-05-01 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
AU2002244337B2 (en) 2000-10-18 2005-08-11 Glaxosmithkline Biologicals S.A. Vaccines
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20050238660A1 (en) * 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0401239D0 (en) * 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions

Also Published As

Publication number Publication date
CA2340174A1 (en) 2000-02-24
US7858589B2 (en) 2010-12-28
DK1104306T3 (da) 2006-05-22
WO2000009159A9 (en) 2000-07-27
EP1104306B1 (de) 2006-01-11
EP1104306A1 (de) 2001-06-06
ES2257068T3 (es) 2006-07-16
AU5395399A (en) 2000-03-06
US7049302B1 (en) 2006-05-23
WO2000009159A1 (en) 2000-02-24
US20060177458A1 (en) 2006-08-10
CA2340174C (en) 2011-01-04
DE69929444T2 (de) 2006-09-28
AU773204B2 (en) 2004-05-20
PT1104306E (pt) 2006-05-31
AU773204C (en) 2005-05-19
JP2002522510A (ja) 2002-07-23
DE69929444D1 (de) 2006-04-06
JP4620251B2 (ja) 2011-01-26

Similar Documents

Publication Publication Date Title
ATE315405T1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
ATE475668T1 (de) Immunisierung durch impfung von dns transkriptionseinheit
MY125202A (en) Vaccine
NO20015073L (no) Vaksiner
HUP0103085A1 (hu) Készítmények és eljárások poliszacharid elleni immunválasz kiváltására
ATE426412T1 (de) Adjuvante influenza-vakzine
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
DE60037900D1 (de) Chlamydia antigene und entsprechende dna-fragmente und ihre verwendungen
EP1467771A4 (de) Mycobakterieller impfstoff
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
SE9903534D0 (sv) Vaccin
MY127452A (en) Vaccines.
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
DK1227840T3 (da) Adjuverede, genetiske vacciner
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
BR0013574A (pt) Antìgeno vacina de moraxella

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1104306

Country of ref document: EP